News | Interventional Radiology | August 20, 2019

Boston Scientific Closes Acquisition of BTG plc

Transaction brings BTG’s Interventional Medicine portfolio under Boston Scientific

Boston Scientific Closes Acquisition of BTG plc

August 20, 2019 — Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.

BTG has three key businesses, the largest of which is its Interventional Medicine portfolio. This encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease.

In addition to the Interventional Medicine product lines, the BTG portfolio also includes: 

  • A specialty pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins; and 
  • A licensing business that receives royalties related to BTG intellectual property and product license agreements.

Upon the effectiveness of the scheme of arrangement, BTG became a wholly-owned subsidiary of Boston Scientific, and BTG shares no longer trade on the London Stock Exchange. Under the terms of the previously announced transaction, holders of BTG common shares will receive 840 pence in cash per share.

Boston Scientific expects to complete the previously announced sale of its global embolic microspheres portfolio – comprised of Embozene, Embozene Tandem and Oncozene brands – to Varian Medical Systems Inc. in due course. The products in question are used to treat arteriovenous malformations and hypervascular tumors. This transaction was entered into in connection with obtaining the antitrust clearances required to complete the BTG transaction.

Read the article “Varian Purchasing Embolic Bead Assets from Boston Scientific”

In addition, the company is initiating a process to explore the divestiture of the royalty stream associated with BTG's Zytiga licensing arrangements and anticipates closing this divestiture by the end of 2019.

The transaction is expected to be immaterial to adjusted earnings per share in 2019 as a result of the BTG transaction closing later than originally anticipated, the divestiture of the Boston Scientific embolic microspheres portfolio, and the treatment of the licensing business as an asset for accounting purposes and its intended divestiture. The transaction is expected to be four to five cents accretive in 2020 on an adjusted basis, and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive as the case may be, due to amortization expense and acquisition-related net charges.

The acquisition of BTG is the second interventional oncology-related acquisition by Boston Scientific in the last year. In October 2018, the company finalized the acquisition of Augmenix Inc., developer of the SpaceOAR hydrogel system to limit common and debilitating side effects of prostate cancer radiotherapy. 

Read the article “Boston Scientific Closes Acquisition of Augmenix Inc.”

For more information: www.bostonscientific.com

Related Content

The radiology industry is saddened to learn of the passing of another leader to COVID-19. Franklin Wilfred Sequeira, M.D., 72, of Cicero, Ind., passed away June 1, 2020. He was just short of celebrating his 40th year working with Radiology of Indiana as an interventional radiologist, never missing a day of work.

Franklin Wilfred Sequeira, M.D.

News | Coronavirus (COVID-19) | June 13, 2020
June 13, 2020 — The r
Chief among the myriad practical updates to minimize risks for patients and imaging personnel alike is a tiered approach for delaying both outpatient and inpatient cross-sectional interventional procedures

For procedural delays that will not adversely affect patient outcome, Fananapazir and colleagues proposed the following tiered approach for both outpatient and inpatient scenarios: urgent procedures, procedures that should be performed within 2 weeks, procedures that should be performed within 2 months, and procedures that can safely be delayed 2 or 6 months. Courtesy of American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | June 05, 2020
June 5, 2020 — An...
#gadolinium Guerbet announced that it received U.S. Food and Drug Administration (FDA) approval to manufacture Dotarem (gadoterate meglumine) injection at its Raleigh, N.C., facility
News | Interventional Radiology | April 21, 2020
April 21, 2020 — Guerbet announced that it received U.S.
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
DSA image obtained approximately 24 hours after 1 mg/h IA tPA infusion, 500 U/h heparin via peripheral IV, and daily oral aspirin (81 mg) shows improved perfusion of digital arteries, albeit with suboptimal vascular blush of distal second and third phalanges

DSA image obtained approximately 24 hours after 1 mg/h IA tPA infusion, 500 U/h heparin via peripheral IV, and daily oral aspirin (81 mg) shows improved perfusion of digital arteries, albeit with suboptimal vascular blush of distal second and third phalanges. Photo courtesy of ARRS

News | Interventional Radiology | February 07, 2020
February 7, 2020 — An ahead-of-print...
Harel Gadot

Harel Gadot, Founder, Executive Chairman and President at XACT Robotics says their system’s small footprint and high mobility design will enable care providers to treat a broad range of patient care needs.

News | Interventional Radiology | November 01, 2019
November 1, 2019 — XACT Robotics Ltd. announced that its firs
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Interventional Radiology | October 28, 2019
October 28, 2019 — Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from im
Exact Imaging Receives FDA 510(k) Clearance for Sterile Transperineal Needle Guide
Technology | Ultrasound Imaging | October 24, 2019
Exact Imaging received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sterile Transperineal Needle...